All Stories

  1. Analytical Validation and Quality Control/Quality Assurance Practices for Improved Rigor and Reproducibility of Biochemical Assays in Orthopaedic Research
  2. A commentary on “A rapid, sensitive and specific assay to measure TF activity based on chromogenic determination of thrombin generation”
  3. Thrombosis and novel hemophilia therapies: the fine line between clotting and bleeding
  4. EPCR knockout: inflaming the discussion
  5. A unique protein kinase C-dependent pathway for tissue factor downregulation in pericytes
  6. The impact of prothrombin complex concentrates when treating DOAC-associated bleeding: a review
  7. The next best thing in factor VIIa
  8. Human platelets express endothelial protein C receptor, which can be utilized to enhance localization of factor VIIa activity
  9. The Tissue Factor Pathway and Wound Healing
  10. Differentiating between cold agglutinins and rouleaux: a case series of seven patients
  11. Impact of Non–Vitamin K Antagonist Oral Anticoagulants From a Basic Science PerspectiveHighlights
  12. Abnormal joint and bone wound healing in hemophilia mice is improved by extending factor IX activity after hemarthrosis
  13. No association between donor age and recipient outcomes: transfusion of plasma in patients undergoing coronary artery bypass grafting surgery
  14. An activated factor VII variant with enhanced tissue factor-independent activity speeds wound healing in a mouse hemophilia B model
  15. Reversal of Dabigatran Effects in Models of Thrombin Generation and Hemostasis by Factor VIIa and Prothrombin Complex Concentrate
  16. Cell-Mediated Hemostasis
  17. Coated platelet assay: a feasible approach to a complicated science
  18. Coated platelets and severe haemophilia A bleeding phenotype: Is there a connection?
  19. Coagulation in Liver Disease
  20. Novel oral anticoagulants and reversal agents: Considerations for clinical development
  21. Reversal of Dabigatran Effects in Models of Thrombin Generation and Hemostasis by Factor VIIa and Prothrombin Complex Concentrate
  22. Fibrinogen-Coated Nanospheres Prevent Thrombocytopenia-Related Bleeding
  23. 161: Effect of antifibrinolytic drugs on in vitro clot formation among peripartum women
  24. Reversing targeted oral anticoagulants
  25. Hemostasis: Old System, New Players, New Directions
  26. A mouse bleeding model to study oral anticoagulants
  27. Engineering a new generation of hemostatic agents: highlights of the Scientific Session on Hemostasis at the 2013 meeting of the American Society of Hematology
  28. Theories of Blood Coagulation: Basic Concepts and Recent Updates
  29. Reversing the new oral anticoagulants with prothrombin complex concentrates (PCCs): what is the evidence?
  30. Progressive improvement in wound healing with increased therapy in haemophilia B mice
  31. Superactivated Platelets: Thrombus Regulators, Thrombin Generators, and Potential Clinical Targets
  32. Bleeding risk in warfarinized patients with a therapeutic international normalized ratio: the effect of low factor IX levels
  33. Practical coagulation for the blood banker
  34. Low intensity laser therapy speeds wound healing in hemophilia by enhancing platelet procoagulant activity
  35. Mechanisms and monitoring of bypassing agent therapy
  36. The clotting system - a major player in wound healing
  37. Consequences of intra-articular bleeding in haemophilia: science to clinical practice and beyond
  38. Hemostatic properties of the FVIIa analog NN1731
  39. The multiple roles of tissue factor in wound healing
  40. Hypothesis: Hyperhomocysteinemia is an indicator of oxidant stress
  41. Homocysteinylated fibrinogen forms disulfide-linked complexes with albumin
  42. Platelet binding and activity of a factor VIIa variant with enhanced tissue factor independent activity
  43. Prophylactic correction of the international normalized ratio in neurosurgery: a brief review of a brief literature
  44. Editorial: International normalized ratio
  45. Inflammation does not predispose to bleeding in hemophilia
  46. Heparins: Clinical Use and Laboratory Monitoring
  47. Wound healing in haemophilia - breaking the vicious cycle
  48. Wound healing in hemophilia B mice and low tissue factor mice
  49. Platelet binding and activity of recombinant factor VIIa
  50. Regulation of Hemostasis and Thrombosis
  51. Contributors
  52. Heparin cofactor II in atherosclerotic lesions from the Pathobiological Determinants of Atherosclerosis in Youth (PDAY) study
  53. Platelet functions beyond hemostasis
  54. Synergistic effect of aptamers that inhibit exosites 1 and 2 on thrombin
  55. A rationally designed heparin, M118, has anticoagulant activity similar to unfractionated heparin and different from Lovenox in a cell-based model of thrombin generation
  56. Tissue Factor in Brain Is Not Saturated With Factor VIIa: Implications for Factor VIIa Dosing in Intracerebral Hemorrhage
  57. Celecoxib does not delay cutaneous wound healing in haemophilia B mice
  58. The Coagulation Cascade in Cirrhosis
  59. Dysregulation of Hemostasis by Cancer
  60. FVIIa: you've come a long way, baby!
  61. Animal models of bleeding and tissue repair
  62. Alterations of Fibrinogen Structure in Human Disease
  63. Some things I thought I knew about tissue factor that turn out to be wrong
  64. Perivascular tissue factor is down-regulated following cutaneous wounding: implications for bleeding in hemophilia
  65. Hypercoagulation and thrombophilia in liver disease
  66. Restoring hemostatic thrombin generation at the time of cutaneous wounding does not normalize healing in hemophilia B
  67. Tissue factor around dermal vessels has bound factor VII in the absence of injury
  68. Review article: the prothrombin time test as a measure of bleeding risk and prognosis in liver disease
  69. Elevated prothrombin level and shortened clotting times in subjects with type 2 diabetes
  70. Coagulation 2006: A Modern View of Hemostasis
  71. Pro-thrombotic and pro-oxidant effects of diet-induced hyperhomocysteinemia
  72. Fathers of modern coagulation
  73. Cutaneous wound healing is impaired in hemophilia B
  74. Circulating tissue factor accumulates in thrombi, but not in hemostatic plugs
  75. Manipulation of prothrombin concentration improves response to high-dose factor VIIa in a cell-based model of haemophilia
  76. A Cell-Based Model of Thrombin Generation
  77. Modification of Fibrinogen by Homocysteine Thiolactone Increases Resistance to Fibrinolysis:  A Potential Mechanism of the Thrombotic Tendency in Hyperhomocysteinemia †
  78. Why Are Young College Women Not Using Condoms? Their Perceived Risk, Drug Use, and Developmental Vulnerability May Provide Important Clues to Sexual Risk
  79. What Does It Take to Make the Perfect Clot?
  80. Coagulation disorders and hemostasis in liver disease: Pathophysiology and critical assessment of current management
  81. High dose factor VIIa improves clot structure and stability in a model of haemophilia B
  82. Protein C inhibitor (plasminogen activator inhibitor-3) expression in the CWR22 prostate cancer xenograft
  83. Platelet Heterogeneity: Variation in Coagulation Complexes on Platelet Subpopulations
  84. One more way that mice and men are different
  85. Rethinking the Coagulation Cascade
  86. The Cellular Basis of Traumatic Bleeding
  87. New Concepts in Managing Catastrophic Bleeding: A Combat Perspective
  88. A Systematic Evaluation of the Effect of Temperature on Coagulation Enzyme Activity and Platelet Function
  89. UNDERSTANDING AND MANAGING COAGULOPATHIC BLEEDING
  90. Impact of procoagulant concentration on rate, peak and total thrombin generation in a model system
  91. Differences in the metabolic response to exogenous homocysteine in juvenile and adult rabbits
  92. Safety profile of recombinant factor VIIa
  93. The Potential Role of Factor VIIa in Transfusion Medicine
  94. Laboratory Monitoring of High-Dose Factor VIIa Therapy
  95. The Effect of Temperature and pH on the Activity of Factor VIIa: Implications for the Efficacy of High-Dose Factor VIIa in Hypothermic and Acidotic Patients
  96. Localization of heparin cofactor II in injured human skin: a potential role in wound healing
  97. A cell-based model of coagulation and the role of factor VIIa
  98. Remodeling the Blood Coagulation Cascade
  99. Protease-Activated Receptor-2 Signaling Triggers Dendritic Cell Development
  100. New Insights into the Coagulation System and Implications for New Therapeutic Options with Recombinant Factor VIIa
  101. Elevated prothrombin results in clots with an altered fiber structure: a possible mechanism of the increased thrombotic risk
  102. Elevated plasma homocysteine leads to alterations in fibrin clot structure and stability: implications for the mechanism of thrombosis in hyperhomocysteinemia
  103. The action of high-dose factor Vlla (FVIIa) in a cell-based model of hemostasis
  104. The action of high-dose factor VIIa (FVIIa) in a cell-based model of hemostasis
  105. The action of high-dose factor VIIa (FVIIa) in a cell-based model of hemostasis
  106. Analyzing fibrin clot structure using a microplate reader
  107. Platelets and Thrombin Generation
  108. Activated protein C cleaves factor Va more efficiently on endothelium than on platelet surfaces
  109. FLT3 internal tandem duplication mutations are rare in agnogenic myeloid metaplasia
  110. Circulating and binding characteristics of wild-type factor IX and certain Gla domain mutants in vivo
  111. Generation of Species Cross-reactive Aptamers Using “Toggle” SELEX
  112. Exposure of Mice to Topical Bovine Thrombin Induces Systemic Autoimmunity
  113. The action of high-dose factor VIIa (FVIIa) in a cell-based model of hemostasis
  114. High-dose factor VIIa increases initial thrombin generation and mediates faster platelet activation in thrombocytopenia-like conditions in a cell-based model system
  115. Hemophilia Care in the New Millennium
  116. Inhibition of human and pig thrombin by a high-affinity nuclease-resistant RNA aptamer
  117. Coagulation factor XI is a contaminant in intravenous immunoglobulin preparations
  118. Deencryption of Cellular Tissue Factor Is Independent of Its Cytoplasmic Domain
  119. Platelets induce sinusoidal endothelial cell apoptosis upon reperfusion of the cold ischemic rat liver
  120. The Factor VII-Platelet Interplay: Effectiveness of Recombinant Factor VIIa in the Treatment of Bleeding in Severe Thrombocytopathia
  121. Links Between the Immune and Coagulation Systems: How Do "Antiphospholipid Antibodies" Cause Thrombosis?
  122. Coagulation factor XI is a contaminant in intravenous immunoglobulin preparations
  123. Platelets from Thrombocytopenic Ponies Acutely Infected with Equine Infectious Anemia Virus Are Activated in Vivo and Hypofunctional
  124. Chemistry and Biology of Serpins Edited by Frank C. Church, Dennis D. Cunningham, David Ginsburg, Maureane Hoffman, Stuart R. Stone, and Douglas M. Tollefsen. Plenum Press:  New York. 1997. xvii + 358 pp. $95.00. ISBN 0-306-45698-2.
  125. A randomized trial of recombinant human interleukin-11 following autologous bone marrow transplantation with peripheral blood progenitor cell support in patients with breast cancer
  126. Platelet activity of high-dose factor VIIa is independent of tissue factor
  127. From antiphospholipid syndrome to antibody-mediated thrombosis
  128. Chemistry and Biology of Serpins
  129. Variability in platelet procoagulant activity in healthy volunteers
  130. Cellular Interactions in Hemostasis
  131. Thrombin Enhances Monocyte Secretion of Tumor Necrosis Factor and Interleukin-1 Beta By Two Distinct Mechanisms
  132. The Monocyte Monolayer Assay: A Noninvasive Technique for Predicting the Severity of in Utero Hemolysis
  133. Platelet procoagulant complex assembly in a tissue factor-initiated system
  134. Reticulated platelet counts in patients undergoing autologous bone marrow transplantation: An aid in assessing marrow recovery
  135. Heparin cofactor II and thrombin
  136. Platelets contain releasable coagulation factor IX antigen
  137. Platelets contain releasable coagulation factor IX antigen
  138. Platelet activation in patients with thrombotic thrombocytopenic purpura
  139. A Rapid Method to Isolate Platelets from Human Blood by Density Gradient Centrifugation
  140. The effects of heparin cofactor II-derived chemotaxins on neutrophil actin conformation and cyclic AMP levels
  141. Antibody-Coated Erythrocytes Induce Secretion of Tumor Necrosis Factor by Human Monocytes: A Mechanism for the Production of Fever by Incompatible Transfusions
  142. The Effect of Alpha2Macroglobulin-Proteinase Complexes on Macrophage IA Expression in Vivo
  143. PDGF-stimulated fibroblast proliferation is enhanced synergistically by receptor-recognized ?2-Macroglobulin
  144. Variability in the Fibrinogen and Von Willebrand Factor Content of Cryoprecipitate: Implications for Reducing Donor Exposure
  145. Effect of interferon-γ and human α2-macroglobulin on peritoneal macrophage morphology and Ia antigen expression
  146. Production of chemotactic peptides by neutrophil degradation of heparin cofactor II
  147. Comparison of the effects of IL-1α and TNF-α on phagocyte accumulation and murine antibacterial immunity
  148. Alpha-Macroglobulin Secreted by Alveolar Macrophages Serves as a Binding Protein for a Macrophage-derived Homologue of Platelet-derived Growth Factor
  149. α 2Macroglobulin-proteinase complexes stimulate prostaglandin E2 synthesis by peritoneal macrophages
  150. Reduced trypsin-binding capacity of α2-macroglobulin in the peritoneal fluid of women with endometriosis: possible relevance to alterations in macrophase function**Supported by the Career Development Program of the Veterans Administration (M.H.); the J...
  151. The Effect of Fibrin Polymerization Inhibitors on Quantitative Measurements of Plasma Fibrinogen
  152. The macrophage-mediated regulation of hepatocyte synthesis of antithrombin III and α1-proteinase inhibitor
  153. α2-macroglobulin ‘fast’ forms inhibit superoxide production by activated macrophages
  154. Effect of cyclooxygenase inhibitors and protease inhibitors on phorbol-induced stimulation of oxygen consumption and superoxide production by rat pulmonary macrophages
  155. Production of superoxide anion by an nadph-oxidase from rat pulmonary macrophages
  156. Changes in Oxygen Consumption and Phagocytosis in Rat Pulmonary Macrophages Related to Animal Maturation
  157. Adaptation to hyperoxia in the neonatal rat: Kinetic parameters of the oxygen-mediated induction of lung superoxide dismutases, catalase and glutathione peroxidase